IP Library Granted Patent US 9,670,210
Granted Patent B2
US 9,670,210 · App. 14/620,903 · Granted Jun 6, 2017

Cyclopropylamines as LSD1 inhibitors

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,670,210
App. No.
14/620,903
Granted
Jun 6, 2017
Kind
B2
Abstract

The present invention is directed to cyclopropylamine derivatives which are LSD1 inhibitors useful in the treatment of diseases such as cancer.

Claims (16)

1. A compound which is 1-{[4-(methoxymethyl)-4-({[(1R,2S)-2-phenylcyclopropyl]amino}methyl)piperidin-1-yl]methyl}cyclopentanecarboxylic acid, or a pharmaceutically acceptable salt thereof.

2. A compound which is 1-{[4-(methoxymethyl)-4-({[(1R,2S)-2-phenylcyclopropyl]amino}methyl)piperidin-1-yl]methyl}cyclopentanecarboxylic acid.

3. A compound which is 1-{[4-(methoxymethyl)-4-({[(1R, 2S)-2-phenylcyclopropyl]amino}methyl)piperidin-1-yl]methyl}cyclobutanecarboxylic acid, or a pharmaceutically acceptable salt thereof.

4. A compound which is 1-{[4-(methoxymethyl)-4-({[(1R, 2S)-2-phenylcyclopropyl]amino}methyl)piperidin-1-yl]methyl}cyclobutanecarboxylic acid.

5. A compound which is 1-{[4-({[(1R, 2S)-2-(4-fluorophenyl)cyclopropyl]amino}methyl)-4-(methoxymethyl)piperidin-1-yl]methyl}cyclobutanecarboxylic acid, or a pharmaceutically acceptable salt thereof.

6. A compound which is 1-{[4-({[(1R, 2S)-2-(4-fluorophenyl)cyclopropyl]amino}methyl)-4-(methoxymethyl)piperidin-1-yl]methyl}cyclobutanecarboxylic acid.

7. A compound which is 1-{[4-(ethoxymethyl)-4-({[(1R, 2S)-2-phenylcyclopropyl]amino}methyl)piperidin-1-yl]methyl}cyclobutanecarboxylic acid, or a pharmaceutically acceptable salt thereof.

8. A compound of claim 1 , which is 1-{[4-(ethoxymethyl)-4-({[(1R, 2S)-2-phenylcyclopropyl]amino }methyl)piperidin-1-yl]methyl}cyclobutanecarboxylic acid.

9. A pharmaceutical composition comprising the compound of claim 1 , or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier or excipient.

10. A pharmaceutical composition comprising the compound of claim 2 and at least one pharmaceutically acceptable carrier or excipient.

11. A pharmaceutical composition comprising the compound of claim 3 , or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier or excipient.

12. A pharmaceutical composition comprising the compound of claim 4 and at least one pharmaceutically acceptable carrier or excipient.

13. A pharmaceutical composition comprising the compound of claim 5 , or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier or excipient.

14. A pharmaceutical composition comprising the compound of claim 6 and at least one pharmaceutically acceptable carrier or excipient.

15. A pharmaceutical composition comprising the compound of claim 7 , or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier or excipient.

16. A pharmaceutical composition comprising the compound of claim 8 and at least one pharmaceutically acceptable carrier or excipient.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 10, 2021
From: INCYTE CORPORATION
To: INCYTE CORPORATION; INCYTE HOLDINGS CORPORATION
Reel/Frame 058815/0857 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 1, 2015
From: WU, LIANGXING; COURTER, JOEL R.; HE, CHUNHONG; QIAN, DING-QUAN; SHEN, BO; WANG, XIAOZHAO; YAO, WENQING; ZHANG, FENGLEI
To: INCYTE CORPORATION
Reel/Frame 035309/0536 →